리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 273 Pages
라이선스 & 가격 (부가세 별도)
한글목차
가도콰트란 세계 시장은 2030년까지 24억 달러에 달할 전망
2024년에 19억 달러로 추정되는 가도콰트란 세계 시장은 2024년부터 2030년까지 CAGR 3.4%로 성장하여 2030년에는 24억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 스크리닝 용도는 CAGR 2.7%를 기록하며 분석 기간 종료까지 14억 달러에 달할 것으로 예측됩니다. 진단 용도 분야의 성장률은 분석 기간 동안 CAGR 4.6%로 추정됩니다.
미국 시장은 5억 2,780만 달러로 추정, 중국은 CAGR 6.2%로 성장 예측
미국의 가도콰트란 시장은 2024년에 5억 2,780만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 4억 6,620만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.2%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.4%와 2.6%로 예측됩니다. 유럽에서는 독일이 CAGR 1.9%로 성장할 것으로 예측됩니다.
세계의 가도콰트란 시장 - 주요 동향과 촉진요인 정리
가드콰트란이 영상 진단에서 주목받는 이유는?
가도콰트란은 자기공명영상법(MRI)에 사용되는 차세대 대환형 가돌리늄계 조영제(GBCA)입니다. 특히 반복 촬영이 필요한 환자에게 안전성을 높이면서 촬영 성능을 향상시킬 목적으로 개발되었습니다. 가도콰트란의 분자 구조는 가돌리늄 이온을 강력하게 결합시켜 해리의 위험을 최소화하고 가돌리늄이 조직에 잔류할 가능성을 낮춥니다. 이는 이전 세대의 조영제와 관련된 장기적인 가돌리늄 축적에 대한 우려로 인해 중요한 고려사항이 되고 있습니다.
임상 현장에서 가도콰트란은 혈관, 장기, 종양, 병변 등의 병적 구조를 보다 선명하게 묘사하는 데 사용됩니다. 강력한 이완 특성은 저선량으로 고해상도 이미징을 지원하며, 특히 소아 및 신장 기능 장애 환자에서 유용합니다. 신경학, 종양학, 심혈관계 진단에서 고정밀, 고대비 MRI에 대한 수요가 지속적으로 증가하고 있는 가운데, 가도콰트란은 진단의 선명도가 뛰어나고 안전한 대안으로 주목받고 있습니다. 이 제품은 화질과 환자 안전의 양립을 목표로 하는 영상의학과에서 채택되고 있습니다.
제형의 발전과 안전성 프로파일은 어떻게 채택을 뒷받침하고 있는가?
가도콰트란과 같은 대환형 조영제는 화학적 안정성과 유리 가돌리늄 이온의 방출 경향이 낮은 것으로 알려져 있습니다. 가도콰트란은 이러한 토대 위에 운동학적 불활성도를 개선하고 신장 기능이 저하된 환자에서 가돌리늄과 관련된 드물지만 심각한 증상인 신장 전신 섬유증(NSF)의 위험을 감소시키는 효과를 제공합니다. 이러한 특징은 규제 당국에 제출한 신청서와 임상 프로토콜에서 강조되어 가도콰트란을 보다 광범위한 환자군에 적합하게 만들고 있습니다.
이 약물의 임상적 자기장 강도에서의 높은 완화성은 스캔 시간을 단축하고 이미지의 대비를 선명하게 합니다. 이를 통해 보다 효율적인 이미징 워크플로우와 연부조직 이상 검출의 진단 정확도를 향상시킬 수 있습니다. 표준 MRI 장비 및 조영제 공급 시스템과의 호환성을 통해 기존 영상 진단 설정에 원활하게 통합할 수 있기 때문에 의료 서비스 제공자는 인프라를 크게 업그레이드하지 않고도 쉽게 전환할 수 있습니다.
어떤 임상 및 규제 동향이 시장의 잠재력을 형성하고 있는가?
MRI 검사 건수는 신경질환, 암 검진, 심혈관질환 평가의 증가로 인해 전 세계적으로 지속적으로 증가하고 있습니다. 이러한 추세에 따라 의료 서비스 제공자들은 안전성 문제를 최소화하면서 우수한 화질을 제공하는 조영제를 요구하고 있습니다. 규제 당국도 조영제의 안전성을 중시하는 태도를 강화하고 있으며, 가돌리늄 방출 위험이 낮은 약물의 사용을 장려하고 있습니다. 가드콰트란은 이러한 선호도에 부합하여 병원과 영상 진단센터가 선호하는 선택이 되고 있습니다.
의료 기관에서의 채택은 임상 가이드라인과 구매 프레임워크에 대순환계 약물이 점점 더 많이 포함되는 것에 의해 뒷받침되고 있습니다. 선진 진단기법을 우대하는 급여 정책도 특히 신흥국 시장에서의 보급을 촉진하고 있습니다. 가돌리늄 체류에 대한 인식이 임상의와 환자들 사이에서 높아짐에 따라, 보다 안전한 조영제에 대한 수요는 계속 증가할 것으로 예상됩니다. 현재 진행 중인 임상 연구를 통해 중추신경계 병변 검출, 소아 방사선학 등 특수 영상 진단 분야에서 가도콰트란의 사용 범위가 확대되고 있습니다.
가도콰트란 시장의 성장은 몇 가지 요인에 의해 주도됩니다...
가도콰트란 시장의 성장은 보다 안전한 가돌리늄 기반 MRI 조영제에 대한 수요 증가, 영상 진단 물량 확대, 약물 제제 기술 개선 등 여러 요인에 의해 주도되고 있습니다. 가돌리늄의 조직 체류에 대한 우려가 커지면서 운동 안정성이 높은 대환형 화합물로 전환되고 있습니다. 가도콰트란의 저용량으로 높은 이완 효과를 제공하는 능력은 신경학, 종양학, 혈관 진단에서 영상 진단 결과의 개선에 도움을 줍니다. 저위험 조영제에 대한 규제적 지원과 진화하는 안전 기준과의 정합성은 병원 및 외래에서 시장 확대를 촉진할 것입니다. 의료 서비스 제공자들이 안전성이 입증된 효율적이고 고해상도 영상 도구를 찾고 있는 가운데, 가드쿼트란은 첨단 MRI 진단의 차세대 대안으로 각광받고 있습니다.
부문
용도(스크리닝 용도, 진단 용도), 최종사용자(병원 최종사용자, 진단 센터 최종사용자, 전문 클리닉 최종사용자, 기타 최종사용자)
조사 대상 기업 사례
Bayer AG
Bracco Imaging S.p.A.
Canon Medical Systems
Curium Pharma
FUJIFILM Holdings Corporation
GE Healthcare
Glenmark Pharmaceuticals
Guerbet Group
Hitachi Medical Systems
Lantheus Medical Imaging
Mallinckrodt Pharmaceuticals
Nihon Medi-Physics
Philips Healthcare
Siemens Healthineers
Sinerga S.p.A.
Shenzhen YHLO Biotech
Simcere Pharmaceutical Group
Shenzhen Wanliyang Medical
Troikaa Pharmaceuticals
Unistar Medical
AI 통합
Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Gadoquatrane Market to Reach US$2.4 Billion by 2030
The global market for Gadoquatrane estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Screening Application, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Diagnosis Application segment is estimated at 4.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$527.8 Million While China is Forecast to Grow at 6.2% CAGR
The Gadoquatrane market in the U.S. is estimated at US$527.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$466.2 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.
Global Gadoquatrane Market - Key Trends & Drivers Summarized
Why Is Gadoquatrane Gaining Attention in Diagnostic Imaging?
Gadoquatrane is a next-generation macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI). It has been developed to offer improved imaging performance with enhanced safety features, particularly for patients requiring repeated scans. Gadoquatrane’s molecular structure provides strong binding of gadolinium ions, minimizing the risk of dissociation and reducing the likelihood of gadolinium retention in tissues. This has become an important consideration following concerns over long-term gadolinium accumulation associated with earlier-generation contrast agents.
In clinical practice, gadoquatrane is used to enhance visualization of blood vessels, organs, and pathological structures such as tumors and lesions. Its strong relaxivity properties support high-resolution imaging at lower doses, which is especially valuable in pediatric and renal-impaired patients. As demand for accurate, high-contrast MRI continues to rise in neurology, oncology, and cardiovascular diagnostics, gadoquatrane is increasingly viewed as a safer alternative with superior diagnostic clarity. The product is being adopted by radiology departments aiming to balance image quality with patient safety.
How Are Formulation Advances and Safety Profiles Supporting Adoption?
Macrocyclic contrast agents like gadoquatrane are known for their chemical stability and low propensity to release free gadolinium ions. Gadoquatrane builds on this foundation by offering enhanced kinetic inertness and reduced risk of nephrogenic systemic fibrosis (NSF), a rare but serious condition linked to gadolinium in patients with impaired kidney function. These characteristics are being emphasized in regulatory filings and clinical protocols, making gadoquatrane suitable for broader patient groups.
Another factor aiding adoption is the agent’s high relaxivity at clinical field strengths, which allows for shorter scan times and sharper image contrasts. This enables more efficient imaging workflows and greater diagnostic precision in detecting soft tissue abnormalities. Compatibility with standard MRI equipment and contrast delivery systems allows seamless integration into existing imaging setups, making it easier for healthcare providers to transition without significant infrastructure upgrades.
What Clinical and Regulatory Trends Are Shaping Market Potential?
MRI scan volumes continue to increase globally, driven by rising incidence of neurological disorders, cancer screening, and cardiovascular disease evaluation. These trends are leading healthcare providers to seek contrast agents that offer superior image quality with minimal safety concerns. Regulatory bodies are increasingly focusing on contrast agent safety, encouraging the use of agents with lower gadolinium release risk. Gadoquatrane aligns well with such preferences, positioning it as a preferred option for hospitals and diagnostic imaging centers.
Institutional adoption is supported by growing inclusion of macrocyclic agents in clinical guidelines and purchasing frameworks. Reimbursement policies that favor advanced diagnostic procedures also support wider uptake, particularly in developed markets. As awareness around gadolinium retention grows among clinicians and patients, demand for safer contrast solutions is expected to continue rising. Ongoing clinical studies are expanding the scope of gadoquatrane in specialized imaging applications, such as CNS lesion detection and pediatric radiology.
Growth in the Gadoquatrane Market Is Driven by Several Factors…
Growth in the gadoquatrane market is driven by several factors including increasing demand for safer gadolinium-based MRI contrast agents, expanding diagnostic imaging volumes, and technological improvements in agent formulation. Rising concern over tissue retention of gadolinium is prompting a shift toward macrocyclic compounds with higher kinetic stability. Gadoquatrane’s ability to deliver high relaxivity at low doses supports improved imaging outcomes in neurology, oncology, and vascular diagnostics. Regulatory support for low-risk contrast agents and alignment with evolving safety standards facilitate market expansion across hospital and outpatient settings. As healthcare providers seek efficient, high-resolution imaging tools with proven safety profiles, gadoquatrane is gaining traction as a next-generation option in advanced MRI diagnostics.
SCOPE OF STUDY:
The report analyzes the Gadoquatrane market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 36 Featured) -
Bayer AG
Bracco Imaging S.p.A.
Canon Medical Systems
Curium Pharma
FUJIFILM Holdings Corporation
GE Healthcare
Glenmark Pharmaceuticals
Guerbet Group
Hitachi Medical Systems
Lantheus Medical Imaging
Mallinckrodt Pharmaceuticals
Nihon Medi-Physics
Philips Healthcare
Siemens Healthineers
Sinerga S.p.A.
Shenzhen YHLO Biotech
Simcere Pharmaceutical Group
Shenzhen Wanliyang Medical
Troikaa Pharmaceuticals
Unistar Medical
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Gadoquatrane - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Safer and More Stable MRI Contrast Agents Drives Clinical Interest in Gadoquatrane Formulations
Increased Concerns Over Gadolinium Retention in Patients With Renal Impairment Spur Development of Macrocyclic Agents Like Gadoquatrane
Growth in MRI Procedures Across Oncology, Neurology, and Cardiovascular Imaging Supports Adoption of Novel Contrast Agents
Advancements in Contrast Agent Design Enhance Stability, Relaxivity, and Diagnostic Accuracy in Gadoquatrane-Based Products
Surge in Gadolinium-Free and Low-Dose Alternatives Positions Gadoquatrane as a Viable Macrocyclic Solution With Enhanced Safety Margins
Expansion of Pediatric and Geriatric Imaging Services Highlights Demand for Well-Tolerated, Low-Toxicity Contrast Media
Improved Shelf-Life, Storage Stability, and Compatibility With MRI Modalities Support Hospital Adoption of Gadoquatrane
Increasing Investment in Radiopharmaceutical R&D Creates Opportunities for Dual-Function Imaging and Contrast Agents
Use in High-Resolution Brain and Vascular Imaging Scenarios Expands Clinical Applications for Gadoquatrane-Based Products
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Gadoquatrane Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Diagnostic Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 24: USA Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: USA 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: USA 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: Canada 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: Canada 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
JAPAN
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: Japan 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: Japan 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
CHINA
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: China Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: China 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: China 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
EUROPE
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: Europe 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
FRANCE
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: France Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: France 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: France 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
GERMANY
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: Germany 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: Germany 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: Italy 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: Italy 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
UNITED KINGDOM
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: UK Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: UK 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: UK 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
SPAIN
TABLE 80: Spain Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Spain Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: Spain 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 83: Spain Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: Spain 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
RUSSIA
TABLE 86: Russia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Russia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: Russia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 89: Russia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: Russia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: Rest of Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
AUSTRALIA
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 107: Australia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Australia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: Australia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 110: Australia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: Australia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
INDIA
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 113: India Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: India Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: India 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 116: India Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: India 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 119: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: South Korea Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: South Korea 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 122: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Rest of Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
LATIN AMERICA
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 131: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 134: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 140: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Argentina Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Argentina 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 143: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
BRAZIL
TABLE 146: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Brazil Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: Brazil 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 149: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
MEXICO
TABLE 152: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Mexico Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: Mexico 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 155: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Rest of Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: Rest of Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
MIDDLE EAST
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 164: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 167: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
IRAN
TABLE 173: Iran Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Iran Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: Iran 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 176: Iran Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: Iran 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
ISRAEL
TABLE 179: Israel Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Israel Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: Israel 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 182: Israel Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: Israel 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Saudi Arabia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: Saudi Arabia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 191: UAE Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: UAE Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: UAE 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 194: UAE Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: UAE 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Rest of Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: Rest of Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
AFRICA
Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 203: Africa Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Africa Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Africa 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
TABLE 206: Africa Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Africa 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030